KU ASCO 2019 Updates on Pancreatic Cancer: Maintenance Olaparib and Gemcitabine Adjuvant Therapy

Forgot your password?

Select specialty

Choose Password

About Us
Careers
Partner with us
F.A.Q
Contact us
Terms & conditions
Privacy policy

Playback speed

August 21, 2019

Integrity CE

M. Pishvaian

2024 ESMO Annual Meeting Insights Hub

2024 ASCO® Annual Meeting Insights Hub

2024 ESMO Annual Meeting Insights Hub

2024 ASCO® Annual Meeting Insights Hub

Yale Cancer Center

Hani Babiker

Harshabad Singh

Aditya Shreenivas

S. Chakrabarti

AdventHealth

2024 ASCO® Annual Meeting Insights Hub

University of Miami Sylvester Comprehensive Cancer Center

2024 ASCO® Annual Meeting Insights Hub

Total Health

Oncology 2024 Year in Review

Insights from 2024 ESMO GI Annual Meeting

T. Seufferlein

Yale Cancer Center

Login

Login

Join VuMedi

KU ASCO 2019 Updates on Pancreatic Cancer: Maintenance Olaparib and Gemcitabine Adjuvant Therapy

Treatment Decisions When Initiating a Tyrosine Kinase Inhibitor and …

Hypothetical Patient Case: Hepatocellular Carcinoma and Consideratio…

Related Videos

How Recent Data Impacts Pancreatic Cancer Management

ESMO 2024 Summary: Updates in Pancreatic Cancer and Impacts on Pract…

ASCO® 2024 Insights: "The GIANT Trial (EA2186) - Gem & nab-Paclitaxe…

ESMO 2024 Summary: Latest Advances in Targeted Therapies for Pancrea…

Updates in Perioperative Therapy of Pancreatic Cancer

ASCO® 2024 Summary: "Advancing GI Cancer Treatment - The Clinical Ut…

NORPACT-1 Trial Updates: Neoadjuvant FOLFIRINOX vs. Upfront Surgery …

Clinical Takeaways in From Recent Key Trials in Pancreatic Cancer

Targeting KRAS in Pancreatic Cancer

Neoadjuvant IO in MSI-High GI Cancers: Special Focus on the DREAM GI…

Pancreatic Adenocarcinoma and Neuroendocrine Tumors - An Update

ASCO® 2024 Insights: "Biomarker-Directed Treatment for Pancreatic Ad…

ASCO® 2024 Insights: "Summary of the PASS-01 Trial - 1L FOLFIRINOX v…

The TAPUR Study: Evaluating Targeted Therapies Based on Genetic Alte…

ASCO® 2024 Insights: "EXPEL-PANC - A Ph2 Study of BXCL701 + Pembro i…

2024 Updates on Targeted Approaches for GI Cancers and New Data in N…

Year in Review 2024 - Transformative FDA Approvals in Precision Onco…

ESMO GI 2024 Insights: Role of Personalized Medicine in Pancreatic C…

GI Oncology Year in Review: Precision Medicine Update in Metastatic …

Perspectives on the Recent FDA Approval of NALIRIFOX in Frontline Me…